论文信息 - Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.

Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions.

9580Background: Currently approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are ineffective in patients (pts) with EGFR exon 20 insertion NSCLC. TAK-788 is an EGFR ...